Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome. The use of nafamostat in Asian countries is approved as an anticoagulant therapy for patients undergoing continuous renal replacement therapy due to acute kidney injury. The directory classifies it as a commercial API with a synthetic source/manufacturing origin. Other names for this substance include Nafamostatum and 6-Amidino2-naphthyl 4-guanidinobenzoate. Its PubChem CID is 4413.
Nafamostat
| CAS No | 81525-10-2 |
|---|---|
| Molecular Formula | C19H17N5O2 |
| Molecular Weight | 347.4 g/mol |
| Synonyms | (6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate |
Zoho Contact Form
"*" indicates required fields
Frequently Asked Questions
Nafamostat is a synthetic serine protease inhibitor that is commonly formulated with hydrochloric acid due to its basic properties. It has been used in trials studying the prevention of Liver Transplantation and Postreperfusion Syndrome.
The listed CAS number is 81525-10-2.
The listed molecular formula is C19H17N5O2.
The listed molecular weight is 347.4 g/mol.
(6-carbamimidoylnaphthalen-2-yl) 4-(diaminomethylideneamino)benzoate.
The source lists Nafamostatum and 6-Amidino2-naphthyl 4-guanidinobenzoate.